En prognostisk transkriptomisk signatur for kronisk hypersensitivitetspneumonitt (PREDICT-HP)
Utvikling og validering av en prognostisk transkriptomisk signatur for kronisk hypersensitivitetspneumonitt
Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
Studieoversikt
Status
Status
Forhold
Forhold
Detaljert beskrivelse
Hypersensitivity pneumonitis is an immunologically mediated form of lung disease, resulting from inhalation exposure to a large variety of antigens. For unknown reasons, a subgroup of patients with HP without a known inciting antigen exposure develops chronic disease with progressive pulmonary fibrosis (the leading cause of death). Accurately identifying patients at risk of disease progression is necessary for prognosis and therapy.
Enrolled subjects will be followed for 24 months and complete 5 visits to one of the study centers. Blood biomarkers will be collected in addition to other clinical data to determine if these biomarkers can predict disease progression.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85719
- University of Arizona
-
-
California
-
Sacramento, California, Forente stater, 95817
- University of California Davis
-
-
Colorado
-
Denver, Colorado, Forente stater, 80206
- National Jewish Health
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- University of Texas Southwestern
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84108
- University of Utah
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The study population consists of men and women aged 18 to 85 years old with a diagnosis of chronic hypersensitivity pneumonitis.
Beskrivelse
Inclusion Criteria:
- Diagnosis of chronic hypersensitivity pneumonitis
- Age 18 through 85 years.
- Diagnosis of chronic hypersensitivity pneumonitis by HRCT
- Able to understand and sign a written informed consent form.
- Able to understand the importance of adherence to the study protocol and willing to follow all study requirements
Exclusion Criteria:
- Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study
- Known explanation for the interstitial lung disease
- Clinical diagnosis of any connective tissue disease
- Listed or expected to receive a lung transplant within 4 months from enrollment
- Pregnant women
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Tid til absolutt FVC-nedgang (prosent predikert) ≥10 prosent
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Tid til absolutt DLCO-nedgang (prosent anslått) ≥10 prosent
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Tid til relativ FVC-nedgang (prosent predikert) ≥10 prosent
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Tid til relativ DLCO-nedgang (prosent anslått) ≥10 prosent
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Tid til relativ DLCO-nedgang (prosent anslått) ≥15 prosent
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Tid til første dømt akutt kronisk hypersensitivitet pneumonitt forverring
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Behov for en ny kur med orale eller intravenøse steroider
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Tid til død uansett årsak
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Endring fra baseline i dyspné ved bruk av St. George's Respiratory Questionnaire aktivitetsscore ved måned 12
Tidsramme: 12 måneder
|
12 måneder
|
|
|
Endre fra baseline i 6-minutters gangavstand ved måned 6
Tidsramme: 6 måneder
|
6 måneder
|
|
|
Endre fra baseline i 6-minutters gangavstand ved måned 12
Tidsramme: 12 måneder
|
12 måneder
|
|
|
Endre fra baseline i 6-minutters gangavstand ved måned 18
Tidsramme: 18 måneder
|
18 måneder
|
|
|
Endre fra baseline i 6-minutters gangavstand ved måned 24
Tidsramme: 24 måneder
|
24 måneder
|
|
|
Nedgang i FVC (prosent anslått) over 24 måneder
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Nedgang i FVC (ml) over 24 måneder
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Nedgang i DLCO (prosent anslått) over 24 måneder
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Nedgang i DLCO (mmol/min/kpa) over 24 måneder
Tidsramme: Inntil 24 måneder
|
Inntil 24 måneder
|
|
|
Change from baseline in St. George's Respiratory Questionnaire total score at month 6
Tidsramme: 6 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
6 months
|
|
Change from baseline in St. George's Respiratory Questionnaire total score at month 12
Tidsramme: 12 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
12 months
|
|
Change from baseline in St. George's Respiratory Questionnaire total score at month 18
Tidsramme: 18 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
18 months
|
|
Change from baseline in St. George's Respiratory Questionnaire total score at month 24
Tidsramme: 24 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
24 months
|
|
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 6
Tidsramme: 6 months
|
Scores range from 0 to 120, with higher scores indicating greater breathlessness. |
6 months
|
|
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 12
Tidsramme: 12 months
|
Scores range from 0 to 120, with higher scores indicating greater breathlessness. |
12 months
|
|
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 18
Tidsramme: 18 months
|
Scores range from 0 to 120, with higher scores indicating greater breathlessness. |
18 months
|
|
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 24
Tidsramme: 24 months
|
Scores range from 0 to 120, with higher scores indicating greater breathlessness. |
24 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 6
Tidsramme: 6 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
6 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 12
Tidsramme: 12 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
12 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 18
Tidsramme: 18 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
18 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 24
Tidsramme: 24 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
24 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 6
Tidsramme: 6 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
6 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 18
Tidsramme: 18 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
18 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 24
Tidsramme: 24 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
24 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 6
Tidsramme: 6 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
6 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 12
Tidsramme: 12 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
12 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 18
Tidsramme: 18 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
18 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 24
Tidsramme: 24 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
24 months
|
|
Change from baseline in CT visual (≥10 percent) score at month 12
Tidsramme: 12 months
|
Visual scores range from 0 to 100, with higher scores indicating more lung fibrosis. |
12 months
|
|
Change from baseline in CT visual (≥10 percent) score at month 24
Tidsramme: 24 months
|
Visual scores range from 0 to 100, with higher scores indicating more lung fibrosis. |
24 months
|
|
Change from baseline in CT quantitative (≥3.4) score at month 12
Tidsramme: 12 months
|
CT quantitative scores range from 0 to no upper limits, with higher scores indicating more lung fibrosis. |
12 months
|
|
Change from baseline in CT quantitative (≥3.4) score at month 24
Tidsramme: 24 months
|
CT quantitative scores range from 0 to no upper limits, with higher scores indicating more lung fibrosis. |
24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Evans Fernández, MD, MS, National Jewish Health
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- R01HL148437 (U.S. NIH-stipend/kontrakt)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .